利伐沙班治疗儿童肿瘤相关性血栓1例报告-东南大学学报医学版

利伐沙班治疗儿童肿瘤相关性血栓1例报告

单位：1. 东部战区总医院临床药学科, 江苏南京 210002;
2. 东部战区总医院淮安医疗区药剂科, 江苏淮安 223001

分类号：R738.1;R973.2

出版年·卷·期（页码）：2020·39·第三期（266-269）

摘要：

目的:验证利伐沙班用于儿童肿瘤相关性血栓抗凝治疗的安全性与有效性。方法:临床药师全程参与1例7岁骨肉瘤患儿中心静脉导管相关性血栓的抗凝治疗药学监护,为其制定个体化的利伐沙班(5 mg,bid)抗凝方案,并通过抗凝门诊监测凝血酶原时间(PT)指标和利伐沙班谷质量浓度,随访抗凝的安全性和有效性。结果:利伐沙班抗凝1个月后患儿左上肢血栓消失,期间监测PT平均值为(12.33±0.88)s,利伐沙班谷质量浓度平均值为(24.67±7.42)ng·ml^-1,均在参考范围内,未出现新发血栓或出血症状。结论:利伐沙班可作为肿瘤相关血栓患儿口服抗凝治疗的一种选择,联合监测血药质量浓度和PT可在一定程度上保证这一特殊人群用药的安全性及有效性。

Objective:To verify the safety and effectiveness of rivaroxaban treating tumor-associated thrombus in children. Methods:A 7-year-old child with osteosarcoma underwent left upper extremity thrombus induced by PICC. Clinical pharmacist established the anticoagulant therapy of rivaroxaban (5 mg, bid) for him. Prothrombin time(PT) and trough concentration of rivaroxaban were monitored. The safety and effectiveness of rivaroxaban were evaluated during through the anticoagulation treatment and 1 month after his discharge. Results:The thrombus was disappeared, no new thrombus or hemorrhage was found. The mean value of PT was (12.33±0.88)s, and the mean value of the trough concentration of rivaroxaban was (24.67±7.42)ng·ml^-1, all of them were within the reference range. Conclusion:Rivaroxaban may be an option for oral anticoagulant therapy in children with tumor-associated thrombosis. Combined monitoring of blood drug concentration and prothrombin time can ensure the safety and effectiveness of drug use in this particular population to some extent.

参考文献：

[1] KHORANA A A,FRANCIS C W,KUDERER N M,et al.Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy[J].J Thromb Haemost,2007,5(3):632-634.
[2] MONAGLE P,CUELLO C A,AUGUSTINE C,et al.American Society of Hematology 2018 Guidelines for management of venous thromboembolism:treatment of pediatric venous thromboembolism[J].Blood Adv,2018,2(22):3292-3316.
[3] STREIFF M B,MILENTIJEVIC D,MCCRAE K,et al.Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer[J].Am J Hematol,2018,93(5):664-671.
[4] YOUNG A M,MARSHALL A,THIRLWALL J,et al.Comparison of an oral factor X a inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism:results of a randomized trial (SELECT-D)[J].J Clin Oncol,2018,36(20):2017-2023.
[5] MONAGLE P,LENSING A W A,THELEN K,et al.Body weight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr):results from three multicentre,single-arm,phase 2 studies[J].Lancet Haematol,2019,6(10):e500-509.
[6] GOSSELIN R C,ADCOCK D M,BATES S M,et al.International Council for Standardization in Haematology(ICSH) recommendations for laboratory measurement of direct oral anticoagulants[J].Thromb Haemost,2018,118(3):437-450.
[7] CHAN A,LENSING A W A,KUBITZA D,et al.Clinical presentation and therapeutic management of venous thrombosis in young children:a retrospective analysis[J].Thromb J,2018,16:29-38.
[8] SIBSON K R,BISS T T,FUMESS C L,et al.BSH Guideline:management of thrombotic and haemostatic issues in paediatric malignancy[J].Br J Haematol,2018,180(4):511-525.
[9] 中国临床肿瘤学会肿瘤与血栓专家委员会.肿瘤相关静脉血栓栓塞症预防与治疗指南(2019 版)[J].中国肿瘤临床,2019,46(13):653-660.
[10] ZWICKER J I,CONNOLLY G,CARRIER M,et al.Catheter-associated deep vein thrombosis of the upper extremity in cancer patients:guidance from the SSC of the ISTH[J].J Thromb Haemost,2014,12(5):796-800.
[11] 张云凤,邹盈,曲玲,等.低分子肝素在不同VTE风险AECOPD患者血栓前抗凝治疗中的应用分析[J].现代医学,2016,44(2):201-204.
[12] NCCN guidelines.Cancer-associated venous thromboembolic disease version 1[EB/OL].http://www.nccn.org,2019-02-28/2019-11-28.
[13] KEY N S,KHORANA A A,KUDERER N M,et al.Venous thromboembolism prophylaxis and treatment in patients with cancer:ASCO clinical practice guideline update[J].J Clin Oncol,2019,37:1-27.
[14] PATEL M R,MAHAFFEY K W,GARG J,et al.Rivaroxaban versus warfarin in nonvalvular atrial fibrillation[J].N Engl J Med,2011,365(10):883-891.
[15] BAUERSACHS R,BERKOWITZ S D,BRENNER B,et al.Oral rivaroxaban for symptomatic venous thromboembolism[J].N Engl J Med,2010,363(26):2499-2510.
[16] ATTARD C,MONAGLE P,KUBITZA D,et al.The in vitro anticoagulant effect of rivaroxaban in children[J].Thromb Res,2012,130:804-807.
[17] ATTARD C,MONAGLE P,KUBITZA D,et al.The in vitro anticoagulant effect of rivaroxaban in neonates[J].Blood Coagul Fibrinolysis,2014,25:237-240.
[18] WILLMANN S,BECKER C,BURGHAUS R,et al.Development of a paediatric population-based model of the pharmacokinetics of rivaroxaban[J].Clin Pharmacokinet,2014,53(1):89-102.
[19] MALE C,LENSING A W A,PALUMBO J S,et al.Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children:a randomised,controlled,phase 3 trial[J].Lancet Haematol,2019,7(1):e18-27.
[20] KUBITZA D,WILLMANN S,BECKA M,et al.Exploratory evaluation of pharmacodynamics,pharmacokinetics and safety of rivaroxaban in children and adolescents:an EINSTEIN-Jr phase I study[J].Thromb J,2018,16:31.
[21] WILLMANN S,THELEN K,KUBITZA D,et al.Pharmacokinetics of rivaroxaban in children using physiologically based and population pharmacokinetic modelling:an EINSTEIN-Jr phase I study[J].Thromb J,2018,16:32.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录